
S5-E22.1 – Healthy Livers, Healthy Lives: Why MASHville Needs This Coalition
In this opening conversation, Healthy LIvers, Healthy Lives Chair Jeff Lazarus discusses the goals of the coalition and two initiative to increase early screening.

In this opening conversation, Healthy LIvers, Healthy Lives Chair Jeff Lazarus discusses the goals of the coalition and two initiative to increase early screening.

EASL Secretary General Aleksander Krag and our other guests, Hannes Hagstrom and Michelle Long, join Jörn Schattenberg and Roger Green to discuss MASLD-related highlights of EASL Congress 2024.

This final conversation from #SLDThinkTank 2024 start with the question, “Next year?” Two key foci emerge: broadening the set of groups in the meeting and focusing more broadly on the concept of preventive hepatology.

This conversation focuses largely on system preparedness and ways to improve scanners and other screening devices. One key point: this becomes more feasible now that Rezdiffra has been approved.

Jeff Lazarus describes the meeting agenda and some of the anticipated outputs, after which other panelists discuss the broad range of issues this design produced.

SLD Think Tank 2023 co-chairs Jörn Schattenberg and Jeff Lazarus and participants Maja Thiele and Mike Betel join Louise Campbell and Roger Green to discuss high points of the recent Barcelona meting.

This closing conversation centers first around Roger’s use of the “blind people touching an elephant” metaphor to describe the complexity of MASH, and then creates a second goal, this time for providers to “rule out the liver.”

Patient advocates Jeff McIntyre (Global Liver Institute) and Mike Betel (Fatty Liver Alliance, Liver Action Network) join Louise Campbell and Roger Green to discuss GLI’s premier MASH patient event, now known as Global Fatty Livery Day.

This conversation includes the rest of the panelists’ hot topics plus Michael Charlton’s dive into FGF-21s.

Michael Charlton joins the Surfers for a far-reaching conversation, with topics ranging from how his clinic is integrating Rezdiffra in MASH patient treatment to exciting research, both reported and in development.